GSA Capital Partners’s OnKure Therapeutics OKUR Stock Holding History

GSA Capital Partners’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92K	Sell	22,224 -23,724	-52%	-$73.2K	0.01%	1566
2025 Q4	$133K	Sell	45,948 -13,276	-22%	-$39.7K	0.01%	1496
2025 Q3	$163K	Buy	59,224 +37,459	+172%	+$92.8K	0.01%	1469
2025 Q2	$52K	Buy	+21,765	New	+$57.1K	﹤0.01%	1660
2024 Q2	–	Sell	-8,802	Closed	-$146K	–	2092
2024 Q1	$146K	Sell	8,802 -685	-7%	-$11.3K	0.01%	1453
2023 Q4	$152K	Buy	+9,487	New	+$591K	0.01%	1367

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GSA Capital Partners's OKUR Position: Q1 2026 in Review

GSA Capital Partners reduced its OnKure Therapeutics (OKUR) stake by 52% in Q1 2026, selling an estimated $73.2K and leaving 22,224 shares worth $92K. The position accounts for 0.01% of the portfolio, ranked #1566.

GSA Capital Partners first reported a position in OKUR in Q4 2023 and has held it in 6 quarters since. The position peaked at $163K in Q3 2025. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

GSA Capital Partners held 22,224 shares of OnKure Therapeutics worth $92K as of Q1 2026.
GSA Capital Partners sold 23,724 OnKure Therapeutics shares in Q1 2026, an estimated $73.2K.
OnKure Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1566 holding.
GSA Capital Partners first reported a position in OnKure Therapeutics in Q4 2023 and has held it in 6 quarters since.
GSA Capital Partners's OnKure Therapeutics position peaked at $163K in Q3 2025.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.